Astex Pharmaceuticals Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
138
- Latest Deal Type
-
M&A
- Financing Rounds
-
9
- Investments
-
5
Astex Pharmaceuticals General Information
Description
Manufacturer of novel small molecule therapeutics products designed to treat cancer and diseases of the central nervous system. The company offers small molecule therapeutics through its proprietary oncology product portfolio and multiple drugs in mid-late stage clinical development and develops novel targeted therapeutics for defined neuro-degenerative disease populations enabling patients with treatment of disease of the central nervous system.
Contact Information
Website
www.astx.com(Operating Subsidiary)
Corporate Office
- 436 Cambridge Science Park
- Cambridge CB4 0QA
- England, United Kingdom
Corporate Office
- 436 Cambridge Science Park
- Cambridge CB4 0QA
- England, United Kingdom
Astex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Astex Pharmaceuticals Comparisons
Industry
Financing
Details
Astex Pharmaceuticals Competitors (83)
One of Astex Pharmaceuticals’s 83 competitors is Tricida, a Formerly VC-backed company based in Sacramento, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tricida | Formerly VC-backed | Sacramento, CA | ||||
| Catalyst Pharmaceuticals | Corporate Backed or Acquired | Coral Gables, FL | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Astex Pharmaceuticals Patents
Astex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023076302-A1 | Process for preparing a benzoate salt of a 1-(3-aminopyrrolidine-1-carbonyl)-3,4-diphenylbenzene compound | Inactive | 26-Oct-2021 | ||
| AU-2022355189-A1 | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | Active | 30-Sep-2021 | ||
| AU-2022355189-B2 | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | Active | 30-Sep-2021 | ||
| EP-4408417-A1 | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | Inactive | 30-Sep-2021 | ||
| EP-4408417-A4 | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator | Inactive | 30-Sep-2021 | A61K31/40 |
Astex Pharmaceuticals Signals
Astex Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Astex Pharmaceuticals Investments & Acquisitions (5)
Astex Pharmaceuticals’s most recent deal was a Early Stage VC with Tolero Pharmaceuticals for . The deal was made on 27-Jul-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tolero Pharmaceuticals | 27-Jul-2012 | Early Stage VC | Drug Discovery | ||
| Astex Therapeutics | 20-Jul-2011 | Merger/Acquisition | Drug Discovery | ||
| Montigen Pharmaceuticals | 04-Apr-2006 | Merger/Acquisition | Drug Discovery | ||
| MetaGen Pharmaceuticals | 31-Oct-2003 | Merger/Acquisition | Biotechnology | ||
| Quark Pharmaceuticals | 30-May-1997 | Later Stage VC | Drug Discovery |
Astex Pharmaceuticals Exits (2)
Astex Pharmaceuticals’s most recent exit was on 27-Jul-2012 from Tolero Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Tolero Pharmaceuticals | 27-Jul-2012 | Completed |
|
||
| Quark Pharmaceuticals | 30-May-1997 | Later Stage VC | Completed |
|
Astex Pharmaceuticals FAQs
-
When was Astex Pharmaceuticals founded?
Astex Pharmaceuticals was founded in 1999.
-
Where is Astex Pharmaceuticals headquartered?
Astex Pharmaceuticals is headquartered in Cambridge, United Kingdom.
-
What is the size of Astex Pharmaceuticals?
Astex Pharmaceuticals has 138 total employees.
-
What industry is Astex Pharmaceuticals in?
Astex Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Astex Pharmaceuticals a private or public company?
Astex Pharmaceuticals is a Private company.
-
What is the current valuation of Astex Pharmaceuticals?
The current valuation of Astex Pharmaceuticals is .
-
What is Astex Pharmaceuticals’s current revenue?
The current revenue for Astex Pharmaceuticals is .
-
How much funding has Astex Pharmaceuticals raised over time?
Astex Pharmaceuticals has raised $118M.
-
Who are Astex Pharmaceuticals’s investors?
Abingworth, Cambridge Enterprise Ventures, Clarke Capital Partners, Gimv, and Industry Ventures are 5 of 9 investors who have invested in Astex Pharmaceuticals.
-
Who are Astex Pharmaceuticals’s competitors?
Tricida, Catalyst Pharmaceuticals, Voyager Therapeutics, Celldex, and ACADIA Pharmaceuticals are some of the 83 competitors of Astex Pharmaceuticals.
-
When was Astex Pharmaceuticals acquired?
Astex Pharmaceuticals was acquired on 11-Oct-2013.
-
Who acquired Astex Pharmaceuticals?
Astex Pharmaceuticals was acquired by Otsuka Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process